Apyx Medical Corporation Stock Price, News & Analysis

Apyx Medical Corporation (NASDAQ:APYX) has received FDA 510(k) clearance for its innovative AYON Body Contouring System™, the first FDA-cleared all-in-one platform for aesthetic surgical procedures. The system integrates multiple functionalities including fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities. AYON incorporates the company's proprietary Renuvion® technology and features advanced LIFT Technology for real-time adjustments. The initial clearance covers various aesthetic treatments including Renuvion for loose skin, ultrasound-assisted liposuction, and electrocoagulation. Apyx plans to expand AYON's capabilities with an additional 510(k) submission for power liposuction later in 2025. The commercial launch is scheduled for the second half of 2025, targeting key opinion leader surgeons in strategic locations. The company aims to capitalize on the growing demand from over 15 million GLP-1 drug users seeking body contouring solutions.

Apyx Medical Corporation (NASDAQ:APYX) reported Q1 2025 financial results showing mixed performance. Total revenue decreased 8% to $9.4M compared to $10.2M in Q1 2024. The Advanced Energy segment grew 6% to $7.9M, driven by strong generator sales and U.S. single-use handpiece growth of 14%. However, OEM revenue declined 45% to $1.5M. Net loss improved significantly, decreasing 45% to $4.2M from $7.6M year-over-year. The company is preparing to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance. The system integrates multiple functions including Renuvion technology, liposuction, and contouring capabilities. For FY2025, Apyx reaffirmed guidance of $47.6M-$49.0M in total revenue.

Apyx Medical Corporation (NASDAQ:APYX) has announced television personality Dolores Catania as Chief of Confidence for their Renuvion brand's Renew You consumer marketing campaign. Catania, known from "The Real Housewives of New Jersey" and "The Traitors," will represent the brand's body contouring technology across marketing initiatives including social media, PR, and physician events.

Renuvion is the only FDA-cleared device for use after liposuction and is backed by over 90 clinical publications. The technology is recognized as the #1 body contouring solution trusted by doctors for addressing loose skin concerns, with 4 out of 5 surgeons agreeing in an independent survey. Catania, who has personal experience with the treatment, will leverage her journey with weight loss and transformation to promote the brand's message of physical and emotional empowerment.

Apyx Medical announced two significant peer-reviewed publications validating the use of their Renuvion technology in abdominal body contouring procedures. The first study, published in Aesthetic Plastic Surgery, was a randomized controlled trial with 76 patients comparing lipoabdominoplasty with and without Renuvion. Results showed higher patient satisfaction and better improvements in skin laxity for the Renuvion group over a 2-year period.

The second study in Aesthetic Surgery Journal Open Forum examined 77 patients undergoing ultrasound-assisted lipoabdominoplasty. The research confirmed that adding Renuvion did not increase complications, despite longer surgical times. Notably, CEO Charlie Goodwin highlighted that with over 15 million patients using GLP-1 drugs, Renuvion is uniquely positioned as the only FDA-cleared device for addressing loose skin post-liposuction in aesthetic procedures.

Apyx Medical (NASDAQ: APYX), manufacturer of proprietary helium plasma and radiofrequency technology Renuvion®, has scheduled its first quarter fiscal year 2025 financial results release for May 8, 2025, before market open.

The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (800-717-1738 for domestic, 646-307-1865 for international) using access code 63341, or through the company's webcast link and Investor Relations website section.

Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. The company's products are supported by over 90 clinical publications.

Renuvion, manufactured by Apyx Medical (NASDAQ: APYX), has won the 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener.' The technology is the first and only FDA-cleared device for use after liposuction in body contouring treatments.

The recognition comes as consumer searches for 'sagging skin' increased by 168.7% in 2024. Renuvion's effectiveness is backed by over 90 evidence-based clinical publications, delivering long-lasting results from a single treatment. The technology combines helium plasma and radiofrequency platform technology for skin tightening and has gained widespread acceptance among plastic surgeons and consumers globally.

According to an independent survey by Wakefield Research, 4 out of 5 board-certified or eligible cosmetic and plastic surgeons in the US consider Renuvion the #1 trusted body contouring technology. The NewBeauty Awards, a leading beauty industry program, selected winners after extensive testing and consultation with board-certified doctors and medical experts.

Apyx Medical (NASDAQ:APYX) reported Q4 2024 financial results with total revenue of $14.2 million, showing mixed performance across segments. Advanced Energy revenue remained flat at $12.1 million, while OEM revenue decreased 16% to $2.1 million.

Key highlights include:

• Single-use handpiece shipments increased 5% overall and 20% in the U.S. year-over-year
• Net loss decreased 52% to $4.6 million compared to Q4 2023
• Adjusted EBITDA loss reduced by 53% to $2.2 million
• Implemented cost-saving restructuring, reducing U.S. workforce by 25%, targeting $4.3 million in annual savings
• Submitted 510(k) for AYON™ Body Contouring System ahead of schedule

For 2025 guidance, Apyx expects:

• Total revenue between $47.6-49.0 million
• Advanced Energy revenue of $39.6-41.0 million
• OEM revenue of approximately $8.0 million
• Operating expenses below $40.0 million

Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.

The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.

Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.

Apyx Medical (NASDAQ:APYX) has released preliminary revenue results for Q4 and full year 2024. The company expects Q4 total revenue between $14.1-14.3 million, down 3-4% year-over-year, with Advanced Energy revenue of $12.0-12.2 million (flat YoY) and OEM revenue of $2.1 million (down 17% YoY).

For full year 2024, total revenue is projected at $48.0-48.2 million, an 8% decrease YoY. Advanced Energy segment expects $38.5-38.7 million (down 11% YoY), while OEM revenue shows growth at $9.5 million (up 6% YoY).

Notable improvements include 25% quarter-over-quarter growth in Advanced Energy sales during Q4, doubled generator unit sales in H2 2024 compared to H1, and strong U.S. single-use handpiece sales. The company plans to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance, targeting the growing market for loose skin treatments, particularly driven by GLP-1 drug-related weight loss.